SRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of E protein and the BRD2/4 BD1 domain, restores E protein-attenuated NF-kappaB activity. SRX3177 exerts broad cytotoxic activity against cancer cells. SRX3177 can be used for the study of anti-SARS-CoV-2 and cancer[1][2].